莫格利珠单抗 T76782

Product Introduction
Bioactivity


英文名: Mogamulizumab

描述: Mogamulizumab (KW-0761) 是一种针对 T 细胞 CC 趋化因子受体 4 的 单克隆抗体。Mogamulizumab 具有抗癌活性，通过抗体依赖性细胞毒性 (ADCC) 消除肿瘤细胞，可用于研究癌症、成人T细胞白血病/淋巴瘤 (ATLL)、皮肤T细胞淋巴瘤(CTCL)。

体外活性: In the presence of PBMCs, Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3)[2].In PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP), Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation[3].Cultured PBMCs from patients with HAM/TSP treated with Mogamulizumab (1 μg/mL, 5 days) eliminate CD4+CCR4+ T cells[3].

体内活性: In a murine xenograft model, Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) inhibits the growth of EBV-positive NK-cell lymphomas when combined with PBMC transplantation[2].In a canine bladder cancer-engrafted mouse model, Mogamulizumab (0.1 mg/kg, i.v., every other day) combined with canine PBMCs (administered every fourth day) inhibits tumor growth[4].Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells in dogs, with no observed adverse effects[4].

存储条件: store at low temperaturestore at -20°C

关键字: KW 0761 | KW0761 | Mogamulizumab

相关产品: Reparixin | UNBS5162 | NUCC-390 | CXCR4-IN-2 | SB-265610 | MSX-122 | E6130 | CXCR7 antagonist-1 | SCH 563705 | CTCE 9908 acetate

莫格利珠单抗 T76782信息由TargetMol中国为您提供，如您想了解更多关于莫格利珠单抗 T76782报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途